Literature DB >> 18474322

The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer.

U Mallick, C Harmer, A Hackshaw.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18474322     DOI： 10.1016/j.clon.2008.03.010

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  7 in total

1.  Low versus high I-131 dose for remnant ablation in differentiated thyroid cancer.

Authors:  Allan Hackshaw; Ujjal Mallick
Journal:  Clin Med Res       Date:  2009-06

2.  Need for Completion Thyroidectomy in Patients Undergoing Lobectomy for Indeterminate and High-Risk Nodules: Impact of Intra-Operative Findings and Final Pathology.

Authors:  Edwina C Moore; Samuel Zolin; Vikram Krishnamurthy; Judy Jin; Joyce Shin; Eren Berber; Allan Siperstein
Journal:  World J Surg       Date:  2020-02       Impact factor: 3.352

Review 3.  Radioiodine for remnant ablation and therapy of metastatic disease.

Authors:  Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

4.  A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.

Authors:  Glenn D Flux; Masud Haq; Sarah J Chittenden; Susan Buckley; Cecilia Hindorf; Kate Newbold; Clive L Harmer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-04       Impact factor: 9.236

5.  EVALUATION OF CARDIOVASCULAR RISK AND MYOCARDIAL PERFUSION IN PATIENTS WITH RADICALLY TREATED DIFFERENTIATED THYROID CARCINOMA AND REPEATED EPISODES OF IATROGENIC HYPOTHYROIDISM.

Authors:  M Saftencu; E Barbus; C Pestean; A Piciu; D Piciu
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Jan-Mar       Impact factor: 0.877

6.  Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases.

Authors:  Khalid Hussain Al-Qahtani; Mushabbab Al Asiri; Mutahir A Tunio; Naji J Aljohani; Yasser Bayoumi; Iqbal Munir; Ayman AlAyoubi
Journal:  Clin Ophthalmol       Date:  2014-12-05

7.  Impact of thyroiditis on 131I uptake during ablative therapy for differentiated thyroid cancer.

Authors:  Eugenie S Lim; Shanty G Shah; Mona Waterhouse; Scott Akker; William Drake; Nick Plowman; Daniel M Berney; Polly Richards; Ashok Adams; Ewa Nowosinska; Carmel Brennan; Maralyn Druce
Journal:  Endocr Connect       Date:  2019-05-01       Impact factor: 3.335
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.